Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 229

2.

High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype.

Reikvam H, Aasebø E, Brenner AK, Bartaula-Brevik S, Grønningsæter IS, Forthun RB, Hovland R, Bruserud Ø.

J Clin Med. 2019 Jul 4;8(7). pii: E970. doi: 10.3390/jcm8070970.

3.

Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells.

Nepstad I, Hatfield KJ, Grønningsæter IS, Aasebø E, Hernandez-Valladares M, Hagen KM, Rye KP, Berven FS, Selheim F, Reikvam H, Bruserud Ø.

Signal Transduct Target Ther. 2019 Jun 19;4:20. doi: 10.1038/s41392-019-0050-0. eCollection 2019.

4.

Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia.

Forthun RB, Hellesøy M, Sulen A, Kopperud RK, Sjøholt G, Bruserud Ø, McCormack E, Gjertsen BT.

J Cancer Res Clin Oncol. 2019 Jul;145(7):1729-1749. doi: 10.1007/s00432-019-02931-1. Epub 2019 May 20.

5.

Treatment of acute myeloid leukaemia in elderly patients.

Reikvam H, Dalgaard J, Johansen S, Tvedt THA, Bruserud Ø.

Tidsskr Nor Laegeforen. 2019 Apr 26;139(8). doi: 10.4045/tidsskr.18.0775. Print 2019 May 7. Norwegian.

6.

Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

Brattås MK, Reikvam H, Tvedt THA, Bruserud Ø.

Expert Opin Investig Drugs. 2019 May;28(5):411-420. doi: 10.1080/13543784.2019.1597052. Epub 2019 Apr 5. Review.

PMID:
30916583
7.

Immunosuppression And Immunotargeted Therapy In Acute Myeloid Leukemia - The Potential Use Of Checkpoint Inhibitors In Combination With Other Treatments.

Leufven E, Bruserud O.

Curr Med Chem. 2019 Mar 24. doi: 10.2174/0929867326666190325095853. [Epub ahead of print]

PMID:
30907305
8.

Thrombotic complications in adult patients with severe single coagulation factor or platelet defects - an overview.

Skaadel H, Bruserud Ø.

Expert Rev Hematol. 2019 Feb;12(2):119-128. doi: 10.1080/17474086.2019.1570126. Epub 2019 Jan 28.

PMID:
30689456
9.

A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia.

Bjørnstad R, Aesoy R, Bruserud Ø, Brenner AK, Giraud F, Dowling TH, Gausdal G, Moreau P, Døskeland SO, Anizon F, Herfindal L.

Mol Cancer Ther. 2019 Mar;18(3):567-578. doi: 10.1158/1535-7163.MCT-17-1234. Epub 2019 Jan 24.

PMID:
30679386
10.

The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome.

Brenner AK, Aasebø E, Hernandez-Valladares M, Selheim F, Berven F, Grønningsæter IS, Bartaula-Brevik S, Bruserud Ø.

Cancers (Basel). 2019 Jan 10;11(1). pii: E73. doi: 10.3390/cancers11010073.

11.

Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators.

Aasebø E, Hernandez-Valladares M, Selheim F, Berven FS, Brenner AK, Bruserud Ø.

Proteomes. 2018 Dec 20;7(1). pii: E1. doi: 10.3390/proteomes7010001.

12.

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Brattås MK, Lilleeng K, Hovland R, Lægreid IJ, Vorland M, Leh F, Bruserud Ø, Gjertsen BT, Reikvam H.

Biomark Res. 2018 Nov 21;6:33. doi: 10.1186/s40364-018-0147-6. eCollection 2018.

13.

S100 Proteins in Acute Myeloid Leukemia.

Brenner AK, Bruserud Ø.

Neoplasia. 2018 Dec;20(12):1175-1186. doi: 10.1016/j.neo.2018.09.007. Epub 2018 Oct 23. Review.

14.

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation.

Reikvam H, Skavland J, Gullaksen SE, Hovland R, Gedde-Dahl T, Bruserud Ø, Gjertsen BT.

Case Rep Hematol. 2018 Sep 23;2018:2045985. doi: 10.1155/2018/2045985. eCollection 2018.

15.

Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors-Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses.

Tvedt THA, Melve GK, Tsykunova G, Ahmed AB, Brenner AK, Bruserud Ø.

Int J Mol Sci. 2018 Sep 22;19(10). pii: E2886. doi: 10.3390/ijms19102886.

16.

Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis.

Nepstad I, Hatfield KJ, Tvedt THA, Reikvam H, Bruserud Ø.

Cancers (Basel). 2018 Sep 14;10(9). pii: E332. doi: 10.3390/cancers10090332.

17.

Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases.

Wendelbo Ø, Opheim EN, Hervig T, Felli Lunde TH, Bruserud Ø, Mollnes TE, Reikvam H.

Vox Sang. 2018 Oct;113(7):657-668. doi: 10.1111/vox.12703. Epub 2018 Aug 29.

PMID:
30159896
18.

Immunological heterogeneity of healthy peripheral blood stem cell donors - preharvesting donor characteristics, additional heterogeneity induced by granulocyte colony-stimulating factor and possible importance for outcome after allotransplantation.

Bruserud Ø, Melve GK, Gedde-Dahl T, Tvedt THA.

Expert Rev Hematol. 2018 Oct;11(10):757-759. doi: 10.1080/17474086.2018.1511420. Epub 2018 Aug 20. No abstract available.

PMID:
30126308
19.

Bone marrow abnormalities detected by magnetic resonance imaging as initial sign of hematologic malignancies.

Grønningsæter IS, Ahmed AB, Vetti N, Johansen S, Bruserud Ø, Reikvam H.

Clin Pract. 2018 Jun 7;8(2):1061. doi: 10.4081/cp.2018.1061. eCollection 2018 Mar 28.

20.

Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood.

Rundgren IM, Bruserud Ø, Ryningen A, Ersvær E.

J Immunol Methods. 2018 Oct;461:53-62. doi: 10.1016/j.jim.2018.06.003. Epub 2018 Jun 12.

PMID:
29906454

Supplemental Content

Loading ...
Support Center